跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 874 条关于
“postsurgical hypoparathyroidism”
全部
874
临床试验
799
药物
4
机构
0
资讯
71
昨天
BridgeBio Plans Four Global Launches by 2027 as Attruby Annualizes Above $1 Billion
2年前
Pembrolizumab Fails to Improve DFS in High-Risk Endometrial Cancer, Shows Promise in dMMR Subgroup
去年
FDA Approves Perioperative Nivolumab for Resectable NSCLC Without EGFR or ALK Mutations
去年
Ascendis Pharma's Yorvipath Commercially Available in the US, Offering New Hope for Hypoparathyroidism
去年
TransCon PTH Shows Sustained 4-Year Efficacy in Hypoparathyroidism Patients
4个月前
Palopegteriparatide Shows Sustained 3-Year Benefits in Hypoparathyroidism Treatment
24天前
Canada's Drug Agency Recommends Conditional Reimbursement for Yorvipath in Chronic Hypoparathyroidism
10个月前
Pacira BioSciences Licenses Novel Long-Acting Ropivacaine Formulation AMT-143 for Postsurgical Pain Management
去年
AstraZeneca's Eneboparatide Meets Primary Endpoint in Phase III Trial for Hypoparathyroidism
去年
MBX Biosciences Completes Enrollment in Phase 2 Trial of Canvuparatide for Hypoparathyroidism
第 1 页，共 8 页
上一页
下一页
